Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Rituximab + zandelisib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Rituximab||Rituxan||IDEC-C2B8|MabThera||CD20 Antibody 17||Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia, and in combination with chemotherapy in pediatric patients (6 month to 18 years of age) with treatment-naive, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia (B-AL) (FDA.gov).|
|zandelisib||ME401|PWT-143|PWT143|ME-401||PIK3CD inhibitor 26||Zandelisib (ME-401) is a selective Pi3kd inhibitor that inhibits PI3K/AKT pathway signaling to decrease cell proliferation and induce cell death (PMID: 31506873).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04745832||Phase III||Rituximab + zandelisib Bendamustine + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate||Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)||Recruiting||USA | ITA | FRA | ESP | CAN | BEL||13|
|NCT02914938||Phase I||zandelisib Rituximab + zandelisib||A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma||Active, not recruiting||USA||1|